Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus vs Progestin or Chemotherapy in Advanced Endometrial Carcinoma
NCT00739830Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2008
- Primary completion
- Feb 2011
- Modality
- Classical Binding Small Molecules
01
Overview
A Phase 2 trial of ridaforolimus in endometrial carcinoma, sponsored by Merck & Co.. Started Aug 2008; status: completed.
02
Drugs
ridaforolimus
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00739830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00739830.